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IMPORTANCE Prostate radiotherapy (RT) improves survival in men with low-burden
metastatic prostate cancer. However, owing to the dichotomized nature of metastatic burden
criteria, it is not clear how this benefit varies with bone metastasis counts and metastatic site.
OBJECTIVE To evaluate the association of bone metastasis count and location with survival
benefit from prostate RT.
DESIGN, SETTING, AND PARTICIPANTS This exploratory analysis of treatment outcomes based
on metastatic site and extent as determined by conventional imaging (computed
tomography/magnetic resonance imaging and bone scan) evaluated patients with newly
diagnosed metastatic prostate cancer randomized within the STAMPEDE trial’s metastasis M1
RT comparison. The association of baseline bone metastasis counts with overall survival (OS)
and failure-free survival (FFS) was assessed using a multivariable fractional polynomial
interaction procedure. Further analysis was conducted in subgroups.
INTERVENTIONS Patients were randomized to receive either standard of care (androgen
deprivation therapy with or without docetaxel) or standard of care and prostate RT.
MAIN OUTCOMES AND MEASURES The primary outcomes were OS and FFS.
RESULTS A total of 1939 of 2061 men were included (median [interquartile range] age, 68
[63-73] years); 1732 (89%) had bone metastases. Bone metastasis counts were associated
with OS and FFS benefit from prostate RT. Survival benefit decreased continuously as the
number of bone metastases increased, with benefit most pronounced up to 3 bone
metastases. A plot of estimated treatment effect indicated that the upper 95% CI crossed the
line of equivalence (hazard ratio [HR], 1) above 3 bone metastases without a detectable
change point. Further analysis based on subgroups showed that the magnitude of benefit
from the addition of prostate RT was greater in patients with low metastatic burden with only
nonregional lymph nodes (M1a) or 3 or fewer bone metastases without visceral metastasis
(HR for OS, 0.62; 95% CI, 0.46-0.83; HR for FFS, 0.57; 95% CI, 0.47-0.70) than among
patients with 4 or more bone metastases or any visceral/other metastasis (HR for OS, 1.08;
95% CI, 0.91-1.28; interaction P = .003; HR for FFS, 0.87; 95% CI, 0.76-0.99; interaction
P = .002).
CONCLUSIONS AND RELEVANCE In this exploratory analysis of a randomized clinical trial, bone
metastasis count and metastasis location based on conventional imaging were associated
with OS and FFS benefit from prostate RT in M1 disease.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT00268476; ISRCTN.com Identifier:
ISRCTN78818544
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Two randomized clinical trials, HORRAD and STAMPEDE,confirmed that prostate radiotherapy (RT) improvessurvival in newly diagnosed, low-metastatic-burden
prostate cancer.1-3 These results have established a broad con-
sensus for addition of prostate RT to standard of care (SOC) for
first-line treatment in men with newly diagnosed, low-
metastatic-burden disease.4-7 However, controversy exists on
how to define low metastatic burden.7 Most criteria dichoto-
mize into low-burden or high-burden subgroups using
combined factors with differing thresholds based on bone
metastasis counts; these have previously been identified as
prognostic in patients with prostate cancer treated with sys-
temic therapy.8-12 Therefore, the threshold effects of bone
metastatic burden for selecting men with newly diagnosed
metastatic prostate cancer (mPCa) who might benefit from
prostate RT have not been evaluated systematically. Also, ow-
ing to the historical nature of setting criteria for metastatic bur-
den, the role of prostate RT in treatment for men presenting
with only nonregional lymph node (NRLN) or visceral metas-
tases has not been reported. Herein, we use data from the
STAMPEDE trial’s M1 RT comparison1 to explore the associa-
tion of bone metastatic burden and the influence of isolated
or concomitant nodal or visceral metastatic sites with treat-
ment outcome following RT.
Methods
Study Participants
Patients randomly allocated to the STAMPEDE trial’s M1 RT
comparison were eligible for study. The first efficacy results
from this comparison have been published previously.1 Briefly,
patients with newly diagnosed mPCa and no contraindica-
tion to RT were randomized 1:1 to SOC or SOC plus prostate
RT. Patients underwent baseline staging imaging per study
protocol prior to randomization. Metastatic sites at baseline
were evaluated by conventional imaging (bone scan and com-
puted tomography/magnetic resonance imaging). Pretreat-
ment bone scans were centralized, and metastasis counts were
analyzed retrospectively. Reviewers were blinded to treat-
ment allocation and outcomes as previously reported.1 The SOC
comprised lifelong androgen deprivation therapy (ADT), with
up-front docetaxel permitted in patients randomized after De-
cember 17, 2015. Where used, docetaxel was planned as six
3-week cycles of 75 mg/m2 with or without prednisolone, 10
mg, daily. Patients allocated to RT received either 55 Gy in 20
daily fractions over 4 weeks or 36 Gy in 6 weekly fractions over
6 weeks. The schedule was nominated before randomiza-
tion. All patients provided written informed consent. The trial
is registered at ClinicalTrials.gov (NCT00268476) and ISRCTN.
com (ISRCTN78818544) and had full regulatory, national ethics
committee, and local site approval. Full details of the
STAMPEDE trial can be found at http://www.stampedetrial.
org, and the trial protocol is in Supplement 1.
Outcomes
The STAMPEDE trial comparison’s primary definitive and in-
termediate outcome measures were overall survival (OS) and
failure-free survival (FFS), and we focus on these outcome mea-
sures. Overall survival was defined as the time from random-
ization to death from any cause, and FFS as the time from ran-
domization to the first of: biochemical failure; progression
locally, in lymph nodes or in distant metastases; or death from
prostate cancer.1 Biochemical failure was defined as a rise in
prostate-specific antigen (PSA) level of 50% greater than the
lowest reported PSA level within 24 weeks of enrollment and
greater than 4 ng/mL (to convert to μg/L, multiply by 1.0); pa-
tients without a decrease of 50% were considered to have bio-
chemical failures at time zero. Patients without the event of
interest were censored at the time last known to be event free.
Secondary outcomes are described in eMethods in Supple-
ment 2. The outcomes data set frozen for the STAMPEDE M1
RT comparison was used for survival analyses.1
Statistical Analysis
All analyses conducted herein are exploratory. To evaluate
whether treatment effect varied by bone metastasis count, a
multivariable fractional polynomial interaction (MFPI) algo-
rithm using a nested Cox regression model was performed. Cox
models were adjusted for minimization factors used at ran-
domization: age (<70 or ≥70 years), N stage (N0/N+/NX), World
Health Organization performance status (0 or 1-2), nonsteroi-
dal anti-inflammatory drug or aspirin use (either or no), and
planned docetaxel use (yes/no), along with metastatic site (only
NRLN, bone ± NRLN or any visceral/other metastasis). Mod-
els with first-degree fractional polynomial, second-degree frac-
tional polynomial, and linear functions of bone metastasis
counts were evaluated, and the interaction model with the low-
est Bayesian information criterion and Akaike information cri-
terion was chosen (see eMethods in Supplement 2). A P value
from a likelihood ratio test of the interaction between treat-
ment group and bone metastasis count is presented. The MFPI
model–estimated treatment effect as a function of bone me-
tastasis count was plotted graphically on the HR scale with 95%
CI. Further details regarding the MFPI have been published
previously.13,14 Sensitivity analysis was also undertaken using
Cox models adjusted for selected clinically relevant baseline
Key Points
Question Are bone metastatic burden and site associated with
survival benefit from the addition of prostate radiotherapy (RT) to
standard-of-care systemic therapy in newly diagnosed metastatic
prostate cancer?
Findings This exploratory analysis of 1939 participants in a
randomized clinical trial shows that survival benefit following
prostate RT gradually diminished with increasing bone metastasis
number, with survival benefit most pronounced in patients with
up to 3 bone metastases. Prostate RT was associated with greater
overall and failure-free survival in patients with only nonregional
lymph node metastasis (M1a) or 3 or fewer bone metastases
without visceral metastasis.
Meaning In patients with prostate cancer, bone metastatic
burden and metastasis location may be useful in predicting
survival benefit from prostate RT.
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variables: age, pre-ADT PSA level, World Health Organization
performance status, T stage, Gleason score, N stage, planned
docetaxel use, nominated RT schedule, and metastatic sites.
As a check for interactions identified using MFPI proce-
dures, we conducted 3 further analyses. We evaluated treat-
ment effects within nonoverlapping subpopulations based on
bone metastasis count. If there were insufficient numbers of
patients within subpopulations based on bone metastasis
count, we collapsed them to achieve groups of reasonable size.
We then conducted further analysis within subgroups based
on bone metastasis count cutoff and metastatic sites. Four sub-
groups were created based on these parameters: only NRLN
metastasis (M1a), 3 or fewer and 4 or more bone metastases
(±NRLN), and any visceral/other metastasis. Balance regard-
ing baseline characteristics between treatment arms was evalu-
ated within each subgroup. Kaplan-Meier (KM) estimates were
used to plot survival curves, and relative treatment effects were
evaluated using Cox models within the subgroups. Finally,
based on information obtained from the previous steps, a meta-
static burden classification was devised and evaluated as de-
tailed in eMethods in Supplement 2. An HR below 1 favored
the prostate RT group. Median follow-up was determined
through reverse-censoring on death. Statistical analyses were
performed using Stata, version 15.1 (StataCorp).
Results
Patient Cohort
Following exclusion of patients undergoing nonconventional
imaging (n = 60) and where baseline bone scans could not be
centralized (n = 62), baseline bone scans from 1939 of 2061
(94%) patients with newly diagnosed mPCa randomized
between January 22, 2013, and September 2, 2016, in the
STAMPEDE M1 RT comparison were included (Figure 1).
Baseline characteristics were balanced between the SOC and
the SOC plus RT groups (eTable 1 in Supplement 2) and were
representative of the M1 RT comparison (eTable 2 in Supple-
ment 2). The median (interquartile range [IQR]) age was 68
(63-73) years and the median (IQR) PSA level pre-ADT was 98
(33-313) ng/mL. Of the 1939 patients included, 1587 (82%) had
bone metastases with or without additional NRLN metasta-
sis, 181 (9%) had only NRLN metastasis (M1a), and 171 (9%)
had visceral/other metastasis. Median (IQR) follow-up was 37
(24-48) months.
Bone Metastasis Count–Treatment Interaction
Using the MFPI procedure, the linear model had the lowest
Bayesian information criterion and Akaike information crite-
rion for both OS and FFS outcomes (eResults and eTable 3 in
Supplement 2). There was evidence of heterogeneity of treat-
ment effect on survival for bone metastasis count. A plot of
estimated treatment effect indicated that the survival ben-
efit from prostate RT decreased gradually with increasing bone
metastasis counts. Good evidence of survival benefit with ad-
dition of prostate RT was seen up to 3 bone metastases, with
the upper 95% CI crossing the line of equivalence (HR, 1) just
after this (Figure 2A). Evaluation of relative treatment effect
in nonoverlapping subpopulations based on bone metastasis
counts also showed an HR less than 1 in subpopulations with
3 or fewer bone metastases (eFigure 1 in Supplement 2). In sub-
populations of patients with 1, 2, and 3 bone metastases, pros-
tate RT was associated with an absolute improvement of 8.5%,
6.2%, and 5.8% in 3-year KM estimated survival, respectively
(eFigure 2A in Supplement 2). Beyond 4 bone metastases,
the estimated survival benefit from prostate RT decreased
Figure 1. Flowchart Showing Inclusion of Patients for Bone Metastatic Burden Analysis
4697 Patients randomized to STAMPEDE trial platform
between January 22, 2013, and September 2, 2016
2636 Excluded because allocated to
other research arms or not eligible
for this comparison
1029 Randomized to SOC only (arm A) 1032 Randomized to SOC and prostate RT (arm H) 
976 Analyzed for bone metastatic burden 963 Analyzed for bone metastatic burden
2061 Randomized 1:1 to SOC
only (arm A) or SOC and
prostate RT (arm H)
53 Excluded
32 Nonconventional imaging
21 Unable to obtain bone scan
69 Excluded
28 Nonconventional imaging
41 Unable to obtain bone scan
RT indicates radiotherapy; SOC, standard of care.
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continuously, with the point estimate crossing the line of
equivalence at 8 bone metastases. Although the treatment ef-
fect plot suggested some survival benefit in patients with 4 to
7 bone metastases, this was not evident in the analysis based
on subgroups and subpopulations (eTable 4, eFigure 1, and
eFigure 2 in Supplement 2). Similarly, for FFS, there was good
evidence of a treatment interaction with bone metastasis count,
with the upper 95% CI crossing the line of equivalence at
around 9 bone metastases (Figure 2B). Prostate RT was asso-
ciated with absolute improvements of 21.5%, 10.1%, 14.2% and
8.84% in KM estimated 3-year FFS rates in subpopulations of
patients with 1, 2, 3, and 4 bone metastases, respectively (eFig-
ure 2B in Supplement 2). A sensitivity analysis evaluating the
interaction of bone metastasis count with treatment in a mul-
tivariable Cox model adjusted for age, pre-ADT PSA level, T
stage, Gleason score, N stage, metastatic sites, planned do-
cetaxel use, and nominated RT schedule also yielded similar
results for OS and FFS.
We further checked the interaction of bone metastasis
count with treatment outcomes as identified previously by
evaluating treatment effects in the 1587 patients with bone
metastases with or without NRLN, split into 2 subgroups de-
fined by bone metastasis count. A cut point of 3 bone metas-
tases was chosen based on the threshold identified from the
prior MFPI results (for baseline characteristics in subgroups,
see eTable 5 in Supplement 2). In the 577 patients with 3 or
fewer bone metastases with or without NRLN and no visceral
metastasis, prostate RT improved survival (HR, 0.64; 95% CI,
0.46-0.89; 3-year KM estimated survival, 85% with SOC plus
RT and 75% with SOC). There was no evidence of survival ben-
efit from prostate RT in patients with 4 or more bone metas-
tases with or without NRLN (HR, 1.12; 95% CI, 0.93-1.34) (Table
and Figure 3). A sensitivity analysis conducted in 1287 pa-
tients with only bone metastases after excluding patients with
any NRLN or visceral/other metastasis also confirmed this
(eTable 6 and eFigure 3 in Supplement 2).
Only NRLN or Any Visceral/Other Metastasis
Further analysis was undertaken in 181 patients with only NRLN
(M1a) and 171 patients with any visceral/other metastasis (for
baseline characteristics, see eTables 7 and 8 in Supple-
ment 2). In the subgroup of 181 patients with only NRLN
metastasis (M1a), there was a strong indication of survival
benefit from prostate RT (HR, 0.60; 95% CI, 0.33-1.09). The ab-
solute improvement in 3-year survival with prostate RT was
7%, from 73% (SOC) to 80% (SOC plus RT) (Table and Figure 4).
There was good evidence of improvement in FFS from pros-
tate RT with only NRLN metastasis (HR, 0.63; 95% CI, 0.42-
0.94; absolute improvement in 3-year KM estimated FFS of
22%, from 29% with SOC to 51% with SOC plus RT). Similar
analysis in patients with any visceral/other metastasis showed
no evidence of benefit from adding prostate RT on OS or FFS
(OS HR, 0.89; 95% CI, 0.55-1.42; FFS HR, 0.98; 95% CI, 0.68-
1.39) (Table and Figure 4).
Metastatic Burden Classification
Based on the aforementioned results, a metastatic burden clas-
sification was devised, wherein low burden was defined as pa-
tients with only NRLN or 3 or fewer bone metastases with or
without NRLN regardless of axial or extra axial location and
without any visceral/other metastasis. All others fell in to a
high-burden category. Prostate RT improved OS and FFS in pa-
tients with low-metastatic-burden disease (OS HR, 0.62; 95%
CI, 0.46-0.83, P = .001; FFS HR, 0.57; 95% CI, 0.47-0.70,
P < .001) (eTable 9 and eFigure 4 in Supplement 2). There was
heterogeneity in the treatment effect of RT on survival (inter-
action P = .003) and FFS (interaction P = .002; supporting data
reported in eTable 9 in Supplement 2) with a clearer effect for
patients with low-burden than high-burden disease. Addition-
ally, benefit for prostate RT on OS and FFS within patients with
low-burden disease was consistent across age, pre-ADT PSA
level, World Health Organization performance status, Glea-
son score, tumor stage, regional nodal stage, nominated RT



































Interaction P =.03, MFPI procedure Interaction P = .007, MFPI procedure
Estimated treatment effect (solid line) with pointwise 95% CI (shaded area) is
shown for overall survival (A) and failure-free survival (B). The horizontal gray
line at hazard ratio 1.00 denotes equivalence of treatment effects, with values
below 1.00 favoring prostate radiotherapy. MFPI indicates multivariable
fractional polynomial interaction.
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schedule, or planned docetaxel use (all interaction P > .10; sup-
porting data reported in eFigure 5 and eFigure 6 in Supple-
ment 2). Extended results evaluating secondary outcome mea-
sures are presented in eResults in Supplement 2.
Discussion
We have used a systematic approach herein to consolidate the
notion that bone metastasis number based on conventional bone
scan is predictive of survival benefit from adding prostate RT to
SOC in newly diagnosed mPCa. This benefit is most pro-
nounced up to 3 bone metastases; at or below this there is good
evidencethattheadditionofprostateRTtoSOCsystemictherapy
improves OS and FFS in these men. We also present evidence
that men with M1a disease have improved FFS.
How the treatment effect of prostate RT changes with base-
line bone metastasis count is of clinical relevance for patient
selection and future trial designs. The first analysis of the
STAMPEDE M1 RT comparison1 identified that prostate RT was
more effective in the prespecified low-burden subgroup based
on the CHAARTED definition.10 However, it was not clear how
this treatment effect varied based on bone metastasis counts
and whether a higher threshold could be selected. In this study,
we explored this issue systematically, showing that survival
benefit from prostate RT is most pronounced in patients with
up to 3 bone metastases. Overall, OS and FFS benefits are sup-
ported by evidence for up to 3 bone metastases, but benefit is
less certain between 4 and 7 bone metastases and is not clearly
evident above 7. This association between bone metastatic
number and benefit from local treatment also emphasizes the
importance of accurate metastatic burden assessment to se-
lect patients for prostate RT. Another trial, HORRAD,3 in a sub-
group of 160 patients with less than 5 bone metastases, showed
some evidence of OS benefit for combining prostate RT with
ADT compared with ADT alone (HR, 0.68; 95% CI, 0.42-1.10).
However, as bone metastasis counts in HORRAD were catego-
rized into 1 to 4, 5 to 15 and more than 15, a lower cutoff of 3
bone metastases was not considered,3 highlighting the im-
portance of evaluating such effects on a continuous scale.15 Ad-
ditionally, some studies published previously have sug-
gested that patients with any number of bone metastases
confined to the vertebral column are considered low
burden.10,12 However, in our study of nearly 2000 patients, less
than 2% of patients had 4 or more bone metastases solely
within the vertebral column. We could not explore treatment
effects in such patients given the small numbers.
Further exploratory analysis based on metastatic sites in-
dicated survival benefit from prostate RT in patients with only
NRLN metastasis (M1a) but not in those with visceral/other me-
tastasis. There are currently no other randomized clinical trial
data on the role of prostate RT in patients with M1a disease.
We also showed a substantial prostate RT effect on FFS in M1a
disease; the absolute improvement was 22% at 3 years. This
is consistent with a previously reported nonrandomized analy-
sis from STAMPEDE studying RT in N+M0 patients.16 Also, as
NRLN metastatic burden has been shown to be prognostic,17
the role of metastatic NRLN metastasis counts as a predictive
factor warrants additional investigation. Primary-site RT should
therefore be considered as SOC in these men, who in the pres-
ent study constituted 9% of the overall primary M1 caseload.
By contrast, there was no evidence of benefit on FFS or OS in
patients with visceral/other metastasis. Taken together, our
study reinforces the predictive role of nonosseous metastatic
sites within the metastatic burden criteria.
Currently, the definition of low metastatic burden is not
agreed upon internationally; it includes a range of definitions
based on metastasis number (<3 to <10), various sites (bone,
lymph node, and/or visceral metastasis), and different imaging
modalities.2,7,9,10,12,18 All such criteria are based on the prog-
nostic relevance of metastatic sites and their extent. In our
study, we built upon these prognostic criteria to evaluate
Table. Summary of Estimated Treatment Effects for Overall and Failure-Free Survival in Subgroups
Events/patients, No./No.
HR (95% CI)a
3-y KM survival, % Interaction by
bone metastasis
subgroups P valueSOC SOC + RT SOC SOC + RT
Overall survival
Only NRLN metastasis 28/89 21/92 0.60 (0.33-1.09) 73 80
Bone metastases (±NRLN) 303/802 291/785 0.96 (0.82-1.13) 61 64 .006
≤3 bone metastases 81/290 58/287 0.64 (0.46-0.89) 75 85
≥4 bone metastases 222/512 233/498 1.12 (0.93-1.34) 53 52
Any visceral or other metastasis 37/85 35/86 0.89 (0.55-1.42) 53 56
Failure-free survival
Only NRLN metastasis 54/89 46/92 0.63 (0.42-0.94) 29 51
Bone metastases (±NRLN) 598/802 532/785 0.75 (0.67-0.85) 22 30 .004
≤3 bone metastases 184/290 135/287 0.56 (0.45-0.71) 33 53
≥4 bone metastases 414/512 397/498 0.86 (0.75-0.99) 15 16
Any visceral or other metastasis 68/85 64/86 0.98 (0.68-1.39) 19 20
Abbreviations: HR, hazard ratio; KM, Kaplan-Meier; NRLN, nonregional lymph
node metastasis; RT, radiotherapy; SOC, standard of care.
a HRs and 95% CIs are from Cox proportional hazards models adjusted for age
(<70 or 70 years), N stage (N0, N+ or NX), World Health Organization
performance status (0 or 1-2), nonsteroidal anti-inflammatory drug or aspirin
use (uses either or no), and docetaxel use (yes or no). Cox models evaluating
treatment effects in the only-NRLN metastasis subgroup were adjusted for all
variables as stated above except N stage.
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systematically the predictive nature of metastatic burden
based on conventional imaging using bone scan and com-
puted tomography/magnetic resonance imaging. We show
that metastatic burden criteria are not just prognostic; they
are predictive of survival benefit when primary-site prostate
RT is used. The subgroup of patients with only M1a or 3 or
fewer bone metastases (±NRLN) and without any visceral/
other metastasis had an 8% estimated absolute survival ben-
efit at 3 years, whereas patients with bone metastasis counts
greater than this or with visceral/other metastasis had no such
benefit.
Various biologically plausible reasons exist whereby pros-
tate RT could delay metastatic progression and improve sur-
vival in patients with low metastatic burden.19 Phylogenetic
analysis of metastases in mPCa highlights complex meta-
static cascades, wherein both primary-to-metastatic and me-
tastasis-to-metastasis progression is identified.20 Based on this,
we can hypothesize that treating the primary in low-burden
disease may disrupt metastatic dissemination from the pri-
mary and delay metastatic progression. By contrast, with high
burden, metastasis-to-metastasis progression could be the
dominant mode of dissemination; treating the primary in this
setting has minimal benefit. This hypothesis is supported by
the observed heterogeneity in metastatic progression-free sur-
vival in the current study and the HORRAD trial.2 In our study,
an absolute improvement of 7% in 3-year metastatic progres-
sion-free survival is observed with addition of prostate RT in
patients with low-burden disease. Furthermore, a 2020 study21
using the same high-burden and low-burden criteria as de-
vised herein demonstrated that patients with low-burden dis-
ease had a lower fraction of the genome altered, with lower
genomic instability and fewer oncogenic alterations in the
NOTCH, cell cycle, and epigenetic modifier pathways.
Limitations
Several caveats to this exploratory analysis require mention,
including its retrospective nature. Although the data on quan-
titative bone metastatic burden were available for most of the
patients, some patients had to be excluded because their scans
could not be centralized. There was also a lack of information











































Overall survival in ≤3 bone metastases (±NRLN) subcohortA













































Failure-free survival in ≤3 bone metastases (±NRLN) subcohortB













































Overall survival in ≥4 bone metastases (±NRLN) subcohortC













































Failure-free survival in ≥4 bone metastases (±NRLN) subcohortD
HR, 0.86; 95% CI, 0.75-0.99
Overall and failure-free survival by treatment in 1587 patients with bone metastases with or without nonregional lymph node metastasis (NRLN) metastasis
stratified by 3 (A and B) and 4 (C and D) bone metastases. RT indicates radiotherapy; SOC, standard of care.
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on quantitative lymph node and visceral metastasis, which may
also be predictive. However, a sensitivity analysis conducted
in patients with only bone metastasis did not alter the predic-
tive nature of the bone metastatic burden. We are also con-
scious that counting bone metastasis is not an accurate rep-
resentation of bone metastatic volume. We explored this
further in a separate study22 by evaluating bone scans using
the automated bone scan index, which yielded similar re-
sults. Additionally, around 20% of patients in our study re-
ceived docetaxel as their SOC. Currently, there is no evidence
for combined use of RT and docetaxel nor of the effect of com-
bining them with ADT in M1 disease. The value of prostate RT
combined with abiraterone and docetaxel is currently being
tested in the PEACE-1 trial (NCT01957436). Other ongoing trials
are evaluating local treatment in combination with newer
systemic therapies or metastasis-directed treatments. These
trials can further validate metastatic burden as a predictor of
survival benefit from local treatment. Finally, it is unclear how
to translate these data to staging with newer imaging modalities
using 68gallium-labeled ligands of the prostate-specific
membrane antigen (known as 68Ga-PSMA) or whole-body
magnetic resonance imaging, given that these emerging
imaging modalities are more sensitive in detecting occult
metastases. We emphasize that caution is required in
extrapolating these data and cutoffs onto newer sensitive
imaging modalities. These will need similar detailed studies
to ascertain their true individual clinical relevance relative to
their utility in predicting treatment outcome. This will be best
evaluated prospectively within well-powered randomized
clinical trials.
Conclusions
Bone metastatic burden based on conventional imaging is
predictive of OS and FFS benefit when prostate RT is added
to SOC in newly diagnosed mPCa. This beneficial effect is
most pronounced in patients with up to 3 bone metastases,
below which addition of prostate RT to SOC improves
survival in patients without visceral or other metastasis. The
Figure 4. Kaplan-Meier Curves for Overall Survival (OS) and Failure-Free Survival (FFS) by Treatment in Patients With Only Nonregional Lymph Node











































Overall survival in only NRLN metastasis subcohortA













































Failure-free survival in only NRLN metastasis subcohortB













































Overall survival in any visceral/other metastasis subcohortC













































Failure-free survival in any visceral/other metastasis subcohortD
HR, 0.98; 95% CI, 0.68-1.39
Overall and failure-free survival by treatment in patients with only NRLN metastasis (M1a) (A and B) and any visceral or other metastasis (C and D).
RT indicates radiotherapy; SOC, standard of care.
Association of Bone Metastatic Burden With Survival Benefit From Radiotherapy in Prostate Cancer Original Investigation Research
jamaoncology.com (Reprinted) JAMA Oncology Published online February 18, 2021 E7
Downloaded From: https://jamanetwork.com/ on 02/19/2021
criteria for low metastatic burden based on conventional
imaging, predictive of survival benefit from prostate RT in
men with newly diagnosed mPCa, should now also include
men with M1a disease.
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